Summary of results G: Any adverse event within 24 hours in placebo‐controlled studies
Route of administration	Dose (mg)	Number of		Number with outcome/total		Percent with outcome		Relative harm (95% CI)	NNH (95% CI)
		Studies	Participants	Active	Placebo	Active	Placebo
In participants with moderate or severe baseline pain
Oral	25	4	1550	371/956	220/594	39	37	1.1 (1.0 to 1.3)	Not calculated
Oral	50	10	3728	667/2114	389/1614	32	24	1.3 (1.2 to 1.4)	13 (9.7 to 22)
Oral	100	12	3257	931/2171	255/1086	43	23	1.7 (1.5 to 1.9)	5.2 (4.4 to 6.2)
Subcutaneous	4	3	720	313/442	113/278	71	41	1.8 (1.6 to 2.2)	3.3 (2.7 to 4.4)
Subcutaneous	6	9	1342	341/767	137/575	44	24	2.1 (1.8 to 2.5)	4.9 (3.9 to 6.4)
Intranasal	20	2	516	125/331	27/185	38	15	2.9 (2.0 to 4.2)	4.3 (3.3 to 6.3)
In participants with mild baseline pain
Oral	50	6	1242	104/642	43/600	16	7	2.3 (1.6 to 3.2)	11 (8.0 to 18)
Oral	100	4	941	89/471	32/470	19	7	2.7 (1.9 to 4.0)	8.3 (6.1 to 13)